Method for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
A61K-039/385
A61K-039/35
G01N-033/50
G01N-033/569
A61K-039/00
B82Y-005/00
A61K-039/36
A61K-009/127
A61K-009/51
A61K-038/38
A61K-031/192
A61K-009/14
A61K-038/13
A61K-038/18
A61K-047/50
A61K-047/52
A61K-047/54
A61K-047/59
A61K-047/64
A61K-047/69
B82Y-040/00
출원번호
US-0802260
(2015-07-17)
등록번호
US-10039822
(2018-08-07)
발명자
/ 주소
Altreuter, David H.
Griset, Aaron P.
Maldonado, Roberto A.
출원인 / 주소
Selecta Biosciences, Inc.
대리인 / 주소
Wolf, Greenfield & Sacks, P.C.
인용정보
피인용 횟수 :
0인용 특허 :
41
초록
Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
대표청구항▼
1. A method of providing polymeric synthetic nanocarriers, comprising: (i) preparing polymeric synthetic nanocarriers that comprise an immunosuppressant coupled thereto; and(ii) administering the polymeric synthetic nanocarriers to a subject,wherein the load of the immunosuppressant on average acros
1. A method of providing polymeric synthetic nanocarriers, comprising: (i) preparing polymeric synthetic nanocarriers that comprise an immunosuppressant coupled thereto; and(ii) administering the polymeric synthetic nanocarriers to a subject,wherein the load of the immunosuppressant on average across the first population of synthetic nanocarriers is at least 2% but no more than 25% (weight/weight), and wherein at least 80% of the polymeric synthetic nanocarriers, based on the total number of synthetic nanocarriers, have a minimum dimension or maximum dimension that falls within 20% of the average minimum dimension or the average maximum dimension, respectively, of the polymeric synthetic nanocarriers; and wherein the average minimum dimension of the polymeric synthetic nanocarriers, obtained using dynamic light scattering, is greater than 110 nm and the average maximum dimension of the polymeric synthetic nanocarriers, obtained using dynamic light scattering, is less than 500 nm. 2. The method of claim 1, wherein at least 90% of the polymeric synthetic nanocarriers have the minimum dimension or maximum dimension. 3. The method of claim 2, wherein at least 95% of the polymeric synthetic nanocarriers have the minimum dimension or maximum dimension. 4. The method of claim 1, wherein the minimum dimension or maximum dimension falls within 10%. 5. The method of claim 4, wherein the minimum dimension or maximum dimension falls within 5%. 6. The method of claim 1, wherein the average minimum dimension is equal to or greater than 120 nm. 7. The method of claim 6, wherein the average minimum dimension is equal to or greater than 130 nm. 8. The method of claim 7, wherein the average minimum dimension is equal to or greater than 150 nm. 9. The method of claim 8, wherein the average minimum dimension is greater than 200 nm. 10. The method of claim 9, wherein the average minimum dimension is greater than 250 nm. 11. The method of claim 1, wherein the polymeric synthetic nanocarriers are solid polymeric synthetic nanocarriers. 12. The method of claim 1, wherein an APC presentable antigen is also administered to the subject. 13. The method of claim 12, wherein the APC presentable antigen is coupled to the polymeric synthetic nanocarriers. 14. The method of claim 13, wherein the load of the APC presentable antigen on average across the polymeric synthetic nanocarriers is between 1% and 10% (weight/weight). 15. The method of claim 1, wherein the polymeric synthetic nanocarriers comprise a polymer that is a non-methoxy-terminated, pluronic polymer. 16. The method of claim 1, wherein the polymeric synthetic nanocarriers comprise a polyester, polycarbonate, polyamide or polyether. 17. The method of claim 16, wherein the polyester comprises a poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid) or polycaprolactone. 18. The method of claim 17, wherein the polymeric nanoparticles comprise a polyester and a polyester attached to a polyether. 19. The method of claim 18, wherein the polyether comprises polyethylene glycol or polypropylene glycol. 20. The method of claim 1, wherein the aspect ratio on average across the polymeric synthetic nanocarriers is greater than 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:5, 1:7 or 1:10. 21. The method of claim 1, wherein the immunosuppressant comprises a statin, an mTOR inhibitor, a TGF-beta signaling agent, a corticosteroid, an inhibitor of mitochondrial function, a P38 inhibitor, an NF-kappa beta inhibitor, an adenosine receptor agonist, a prostaglandin E2 agonist, a phosphodiesterase 4 inhibitor, an HDAC inhibitor or a proteasome inhibitor. 22. The method of claim 21, wherein the immunosuppressant is an mTOR inhibitor. 23. The method of claim 22, wherein the mTOR inhibitor is rapamycin. 24. The method of claim 1, wherein the APC presentable antigen is a therapeutic protein or portion thereof, an autoantigen or an allergen, or is associated with an autoimmune disease, an inflammatory disease, an allergy, organ or tissue rejection or graft versus host disease.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (41)
Carlsson, Hans; Larsson, Anette; S?derlind, Erik, Antigen delivery system and method of production.
Lee Hye-Jung ; Johnson OluFunmi L. ; Zale Stephen E. ; Tracy Mark A., Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent.
Gourapura, Renukaradhya; Dwivedi, Varun; Binjawadagi, Basavaraj; Torrelles, Jordi, Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome.
Kostka, James Michael; Balaschak, Edward James; Knapp, Thomas Alexander; Charny, John Allie, Large area hermetic encapsulation of an optoelectronic device using vacuum lamination.
Porcelli Steven A. (Brighton MA) Brenner Michael B. (Brookline MA) Beckman Evan M. (Brookline MA), Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said.
Domb Abraham J. (Efrat ILX) Gref Ruxandra (Nancy FRX) Minamitake Yoshiharu (Ota JPX) Peracchia Maria T. (Parma ITX) Langer Robert S. (Newton MA), Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
da Silveira, Airton Monza; Ponchel, Gilles; Duchene, Dominique; Couvreur, Patrick; Puisieux, Francis, Nanoparticles comprising at least one polymer and at least one compound able to complex one or more active ingredients.
Hyon Suong-Hyu (Uji JPX) Ikada Yoshita (Uji JPX), Polylactic acid type microspheres containing physiologically active substance and process for preparing the same.
Hirosue Sachiko ; Mueller Bernhard G.,CHX ; Langer Robert S. ; Mulligan Richard C., Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids.
Setterstrom Jean A. ; Van Hamont John E. ; Reid Robert H. ; Jacob Elliot ; Jeyanthi Ramasubbu ; Boedeker Edgar C. ; McQueen Charles E. ; Jarboe Daniel L. ; Cassels Frederick ; Brown William ; Thies C, Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.